Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab‐treated multiple sclerosis

Brain atrophy is related to clinical deterioration in multiple sclerosis (MS) but its association with intrathecal markers of inflammation or neurodegeneration is unclear. Our aim was to investigate whether cerebrospinal fluid (CSF) markers of inflammation or neurodegeneration are associated with brain volume change in natalizumab‐treated MS and whether this change is reflected in non‐lesional white matter metabolites.

[1]  Roland Kreis,et al.  The trouble with quality filtering based on relative Cramér‐Rao lower bounds , 2016, Magnetic resonance in medicine.

[2]  À. Rovira,et al.  Brain atrophy in natalizumab-treated patients: A 3-year follow-up , 2015, Multiple sclerosis.

[3]  S. Nelson,et al.  Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. , 2014, JAMA neurology.

[4]  H. Wiendl,et al.  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.

[5]  N. Mueller-Lenke,et al.  Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. , 2013, Swiss medical weekly.

[6]  P. Lundberg,et al.  Procedure for quantitative 1H magnetic resonance spectroscopy and tissue characterization of human brain tissue based on the use of quantitative magnetic resonance imaging , 2013, Magnetic resonance in medicine.

[7]  Elizabeth Fisher,et al.  Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes , 2013, Multiple sclerosis.

[8]  M. Filippi,et al.  Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year of treatment): No , 2013, Multiple sclerosis.

[9]  N. de Stefano,et al.  Preventing brain atrophy should be the gold standard of effective therapy in multiple sclerosis (after the first year of treatment): Commentary , 2013, Multiple sclerosis.

[10]  Finn Sellebjerg,et al.  CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis , 2013, Multiple sclerosis.

[11]  A. Giorgio,et al.  Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing–remitting multiple sclerosis: a prospective, 
non‐randomized pilot study , 2013, European journal of neurology.

[12]  C. Enzinger,et al.  CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome , 2013, Multiple sclerosis.

[13]  À. Rovira,et al.  Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes , 2013, Multiple sclerosis.

[14]  B. Casanova,et al.  The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. , 2012, European journal of radiology.

[15]  K. Blennow,et al.  Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis , 2012, PloS one.

[16]  Michael Khalil,et al.  Neurofilaments as biomarkers in multiple sclerosis , 2012, Multiple sclerosis.

[17]  B. Trapp,et al.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis , 2011, Progress in Neurobiology.

[18]  M. Edström,et al.  Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid , 2010, Multiple sclerosis.

[19]  Joakim Lindblad,et al.  Sub-pixel Segmentation with the Image Foresting Transform , 2009, IWCIA.

[20]  M. Valis,et al.  Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. , 2008, Neuro endocrinology letters.

[21]  M. Filippi,et al.  Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis , 2008, Neurology.

[22]  H. Tumani,et al.  Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis , 2006, Multiple sclerosis.

[23]  A. Thompson,et al.  Metabolite changes in early relapsing–remitting multiple sclerosis , 2006, Journal of Neurology.

[24]  Hans Lassmann,et al.  Cortical demyelination and diffuse white matter injury in multiple sclerosis. , 2005, Brain : a journal of neurology.

[25]  J. Kassubek,et al.  Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis , 2005, Multiple sclerosis.

[26]  Anders Wallin,et al.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.

[27]  N. Shahani,et al.  Functions and malfunctions of the tau proteins , 2002, Cellular and Molecular Life Sciences CMLS.

[28]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[29]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[30]  C. Wikkelsø,et al.  Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF , 1996, Journal of neurochemistry.

[31]  C. Wikkelsø,et al.  A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults , 1994, Journal of Neuroscience Methods.

[32]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[33]  C. Gillberg,et al.  A sensitive ELISA for glial fibrillary acidic protein: application in CSF of children , 1992, Journal of Neuroscience Methods.

[34]  A. Minagar.  Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab , 2011 .

[35]  O. D. Leinhard.  Quantitative Magnetic Resonance in Diffuse Neurological and Liver Disease , 2010 .